Citadel Advisors
VYGR icon

Citadel Advisors’s Voyager Therapeutics VYGR Stock Holding History

Citadel Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95K Sell
24,600
-1,600
-6% -$6.3K ﹤0.01% 12056
2025
Q4 		$103K Sell
26,200
-3,900
-13% -$17.3K ﹤0.01% 11613
2025
Q3 		$141K Buy
30,100
+9,200
+44% +$33.3K ﹤0.01% 11582
2025
Q2 		$65K Buy
20,900
+8,000
+62% +$25.8K ﹤0.01% 11636
2025
Q1 		$43.6K Buy
12,900
+6,900
+115% +$32.2K ﹤0.01% 12443
2024
Q4 		$34K Buy
6,000
+400
+7% +$2.58K ﹤0.01% 12756
2024
Q3 		$32.8K Sell
5,600
-6,900
-55% -$50.2K ﹤0.01% 12352
2024
Q2 		$98.9K Buy
12,500
+1,700
+16% +$14.3K ﹤0.01% 10931
2024
Q1 		$101K Buy
10,800
+5,100
+89% +$43.1K ﹤0.01% 11354
2023
Q4 		$48.1K Sell
5,700
-700
-11% -$5.08K ﹤0.01% 11816
2023
Q3 		$49.6K Sell
6,400
-9,500
-60% -$86.7K ﹤0.01% 11771
2023
Q2 		$182K Sell
15,900
-300
-2% -$3.1K ﹤0.01% 10038
2023
Q1 		$125K Sell
16,200
-1,400
-8% -$11.1K ﹤0.01% 10941
2022
Q4 		$107K Sell
17,600
-24,300
-58% -$138K ﹤0.01% 11119
2022
Q3 		$248K Sell
41,900
-4,800
-10% -$30.7K ﹤0.01% 9988
2022
Q2 		$276K Sell
46,700
-46,000
-50% -$311K ﹤0.01% 9980
2022
Q1 		$706K Sell
92,700
-1,200
-1% -$5.35K ﹤0.01% 8554
2021
Q4 		$254K Buy
93,900
+21,600
+30% +$73.7K ﹤0.01% 11318
2021
Q3 		$190K Sell
72,300
-18,200
-20% -$59.1K ﹤0.01% 12061
2021
Q2 		$374K Buy
90,500
+39,500
+77% +$179K ﹤0.01% 10738
2021
Q1 		$240K Buy
51,000
+33,300
+188% +$227K ﹤0.01% 11332
2020
Q4 		$127K Buy
17,700
+6,500
+58% +$62.5K ﹤0.01% 10057
2020
Q3 		$120K Sell
11,200
-1,000
-8% -$11.7K ﹤0.01% 9165
2020
Q2 		$154K Sell
12,200
-2,000
-14% -$23.3K ﹤0.01% 8726
2020
Q1 		$130K Buy
14,200
+1,900
+15% +$21.8K ﹤0.01% 8417
2019
Q4 		$172K Sell
12,300
-3,500
-22% -$50.9K ﹤0.01% 8288
2019
Q3 		$272K Sell
15,800
-600
-4% -$12.6K ﹤0.01% 7700
2019
Q2 		$446K Sell
16,400
-200
-1% -$4.58K ﹤0.01% 6999
2019
Q1 		$318K Buy
+16,600
New +$216K ﹤0.01% 7529
2018
Q4 		– Sell
-16,200
Closed -$307K – 9827
2018
Q3 		$307K Buy
+16,200
New +$311K ﹤0.01% 7520

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors's VYGR Position: Q1 2026 in Review

Citadel Advisors reduced its Voyager Therapeutics (VYGR) stake by 34% in Q1 2026, selling an estimated $756K and leaving 364,664 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #6863.

Citadel Advisors first reported a position in VYGR in Q3 2017 and has held it in 32 quarters since. The position peaked at $8.95M in Q3 2020. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Citadel Advisors held 364,664 shares of Voyager Therapeutics worth $1.41M as of Q1 2026.
  • Citadel Advisors sold 191,982 Voyager Therapeutics shares in Q1 2026, an estimated $756K.
  • Voyager Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6863 holding.
  • Citadel Advisors first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 32 quarters since.
  • Citadel Advisors's Voyager Therapeutics position peaked at $8.95M in Q3 2020.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.